Ceftibuten: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 20: | Line 20: | ||
'''| [[Ceftibuten overdosage|Overdosage]]''' | '''| [[Ceftibuten overdosage|Overdosage]]''' | ||
'''| [[Ceftibuten dosage and administration|Dosage and Administration]]''' | '''| [[Ceftibuten dosage and administration|Dosage and Administration]]''' | ||
'''| [[Ceftibuten | '''| [[Ceftibuten clinical studies|Clinical Studies]]''' | ||
'''| [[Ceftibuten how supplied|How Supplied]]''' | '''| [[Ceftibuten how supplied|How Supplied]]''' | ||
'''| [[Ceftibuten labels and packages|Labels and Packages]]''' | '''| [[Ceftibuten labels and packages|Labels and Packages]]''' | ||
Revision as of 03:38, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Overview
Ceftibuten is a third-generation cephalosporin antibiotic. It is an orally-administered agent, with 2 dosage forms, capsule or oral suspension. It is marketed by Shionogi USA under the trade name Cedax®
Category
Cephalosporins,third generation.
US Brand Names
CEDAX®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | Clinical Studies | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050686s016lbl.pdf